| Company Name: | Keryx Biopharmaceuticals, Incorporated | | Ticker Symbol: | KERX | | | WWW Address: | www.keryx.com | | CEO: | Ron Bentsur | | No. of Employees: | 17 | | Common Issue Type: | CS | | Business Description: | A biopharmaceutical company, focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer.
|
| | | Industry Information: | DRUGS - Drug Manufacturers - Major [more like this] |
| | Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 2.38 |  0.07 | 2.35 | 2.43 | 2.3 | 2.32 | 2.25 | 1053674 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 133.3 | 56.0 | 3.57 | -1.18 | 0.00 | 9.6 | 0.0 | 3.33 - 0.09 |
| | KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 2.31 | $ | | PE Ratio - LTM | 9.6 | |
| Market Capitalisation | 129.3 | mil |
| Latest Shares Outstanding | 56.0 | mil |
| Earnings pS (EPS) | -1.18 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | 0 | % |
| Revenue per Employee | 75,471 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 44.3 | mil |
| Float as % of Shares Outstanding | 92.6 | % |
| Foreign Sales | 0 | mil |
| Domestic Sales | 0 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 31.40 | % |
| Research & Devlopment (R&D) as % of Revenue | 25.20 | % |
| Gross Profit Margin | 0.0 | % |
| EBITDA Margin | 43.8 | % |
| Pre-Tax Profit Margin | 44.4 | % |
| Assets Turnover | 0.7 | % |
| Return on Assets (ROA) | 24.9 | % |
| Return on Equity (ROE) | 32.4 | % |
| Return on Capital Invested (ROCI) | 32.4 | % |
| Current Ratio | 5.4 | |
| Leverage Ratio (Assets/Equity) | 1.3 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.00 | |
| LT Debt/Total Capital | 0.0 | % |
| Working Capital pS | 0.51 | $ |
| Cash pS | 0.60 | $ |
| Book-Value pS | 0.62 | $ |
| Tangible Book-Value pS | 0.57 | $ |
| Cash Flow pS | 0.20 | $ |
| Free Cash Flow pS | -0.09 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 3.70 | |
| Price/Tangible Book Ratio | 4.07 | |
| Price/Cash Flow | 11.3 | |
| Price/Free Cash Flow | -25.1 | |
| P/E as % of Industry Group | 43.0 | % |
| P/E as % of Sector Segment | 56.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | | | | | PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 0.4 | 99 | 6,658 | 7,477 |
| 4 Weeks | 2.45 | 1.96 | 2.00 | 15.5 | 108 | 6,974 | 118,566 |
| 13 Weeks | 3.33 | 1.28 | 1.39 | 66.2 | 155 | 24,442 | 1,490,951 |
| 26 Weeks | 3.33 | 0.69 | 0.70 | 230.0 | 274 | 23,219 | 2,902,426 |
| 52 Weeks | 3.33 | 0.09 | 0.16 | 1343.8 | 1170 | 17,015 | 4,236,771 |
| YTD | 3.33 | 0.09 | - | 948.6 | 856 | 18,035 | 4,093,872 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 2.33 | 2.26 | 2.23 | 1.44 | 1.08 | 3.57 | 4.00 |
| | | | GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 60.75 | 49.5 | 158.47 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 180.74 | NA | -48.00 |
| R&D | -2.83 | NA | -39.57 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 2535.4 | 851.1 | 22.3 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | 0.0 | 0.0 | 0.0 |
| EPS $ | 1.42 | 0.16 | 0.89 |
| | | | SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 34.85 |
| Current Ratio | 2.4 |
| Quick Ratio (Acid Test) | 2.3 |
| Liquidity Ratio (Cash) | 2.31 |
| Receivables Turnover | 8.3 |
| Average Collection Period | 43 |
| Working Capital/Equity | -623.4 |
| Working Capital pS | 0.19 |
| Cash-Flow pS | -1.10 |
| Free Cash-Flow pS | -0.81 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | -6.12 |
| Financial Leverage Ratio (Assets/Equity) | 0.0 |
| Debt Ratio | 105.6 |
| Total Debt/Equity (Gearing Ratio) | 0.00 |
| LT Debt/Equity | 0.00 |
| LT Debt/Capital Invested | -1,439.2 |
| LT Debt/Total Liabilities | 0.0 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 0.00 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 4.07 |
| Tobin's Q Ratio | 4.86 |
| Current P/E Ratio - LTM | 9.60 |
| Enterprise Value (EV)/EBITDA | -2.79 |
| Enterprise Value (EV)/Free Cash Flow | -2.96 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 4.07 |
| Price/Book Ratio - LTM | 3.70 |
| Price/Cash Flow Ratio | 11.3 |
| Price/Free Cash Flow Ratio - LTM | -25.1 |
| Price/Sales Ratio | 5.07 |
| P/E Ratio (1 month ago) - LTM | 9.0 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | 0 |
| P/E as % of Industry Group | 43.0 |
| P/E as % of Sector Segment | 56.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 9.2 |
| PER SHARE FIGURES |
| LT Debt pS | 0.00 |
| Current Liabilities pS | 0.14 |
| Tangible Book Value pS - LTM | 0.57 |
| Book Value pS - LTM | 0.62 |
| Capital Invested pS | -0.03 |
| Cash pS - LTM | 0.60 |
| Cash Flow pS - LTM | 0.20 |
| Free Cash Flow pS - LTM | -0.09 |
| Earnings pS (EPS) | -1.18 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -3,030.32 |
| Free Cash Flow Margin 5YEAR AVG | -5,231.06 |
| Net Profit Margin | 0.0 |
| Net Profit Margin - 5YEAR AVRG. | 0.0 |
| Equity Productivity | -0.86 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | -0.86 |
| Return on Capital Invested (ROCI) | 3551.4 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | -90.9 |
| Assets Productivity | 0.00 |
| Return on Assets (ROA) | -198.5 |
| Return on Assets (ROA) - 5YEAR AVRG. | -68.5 |
| Gross Profit Margin | 0.0 |
| Gross Profit Margin - 5YEAR AVRG. | 63.7 |
| EBITDA Margin - LTM | 43.8 |
| EBIT Margin - LTM | 38.3 |
| Pre-Tax Profit Margin | 0.0 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 0.0 |
| Effective Tax Rate | 0.0 |
| Effective Tax Rate - 5YEAR AVRG. | -0.0 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 7 |
| Revenue per Employee | 75,471 |
| Net Income per Employee | -3,110,647 |
| Average Collection Period | 7 |
| Receivables Turnover | 8.3 |
| Day's Inventory Turnover Ratio | 0 |
| Inventory Turnover | 0.0 |
| Inventory/Sales | 0.0 |
| Accounts Payble/Sales | 359.55 |
| Assets/Revenue | 0.00 |
| Net Working Capital Turnover | 0.14 |
| Fixed Assets Turnover | 0.12 |
| Total Assets Turnover | 0.0 |
| Revenue per $ Cash | 0.10 |
| Revenue per $ Plant | 7.05 |
| Revenue per $ Common Equity | -0.86 |
| Revenue per $ Capital Invested | -0.86 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 1113.7 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 1357.3 |
| Research & Devlopment (R&D) as % of Revenue | 2962.4 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 2962.4 |
|
|  
| | |  |  | |
| |